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rgCpG oligodeoxynucleotides (ODN) are short single-stranded synthetic DNA molecules that activate the immune
system and have been found to be effective for preventing and treating infectious diseases, allergies, and
cancers. Structurally distinct classes of synthetic ODN expressing CpG motifs differentially activate human im-
mune cells. K-type ODN (K-ODN), which have progressed into human clinical trials as vaccine adjuvants and
immunotherapeutic agents, are strong activators of B cells and trigger plasmacytoid dendritic cells (pDCs) to
differentiate and produce tumor necrosis factor–a (TNFa). In contrast, D-type ODN (D-ODN) stimulate large
amounts of interferon-a (IFNa) secretion from pDCs. This activity depends on the ability of D-ODN to adopt
nanometer-sized G quadruplex–based structures, complicating their manufacturing and hampering their pro-
gress into the clinic. In search of a D-ODN substitute, we attempted to multimerize K-ODN into stable nanostruc-
tures using cationic peptides. We show that short ODN with a rigid secondary structure form nuclease-resistant
nanorings after condensation with the HIV-derived peptide Tat(47–57). The nanorings enhanced cellular inter-
nalization, targeted the ODN to early endosomes, and induced a robust IFNa response from human pDCs.
Compared to the conventional K-ODN, nanorings boosted T helper 1–mediated immune responses in mice
immunized with the inactivated foot and mouth disease virus vaccine and generated superior antitumor im-
munity when used as a therapeutic tumor vaccine adjuvant in C57BL/6 mice bearing ovalbumin-expressing EG.7
thymoma tumors. These results suggest that the nanorings can act as D-ODN surrogates and may find a niche for
further clinical applications.en
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 INTRODUCTION
Short single-stranded synthetic oligodeoxynucleotides containing
cytosine-phosphate-guanine motifs (CpG ODN) stimulate the cells of
the innate immune system expressing the pathogen recognition recep-
tor Toll-like receptor 9 (TLR9), generating a robust proinflammatory
immune response (1–4). The extensive interest in the immunother-
apeutic potential of immunostimulatory ODN led to the development
of four structurally different classes of CpG ODN (5). K-class ODN
(K-ODN; also known as CpG-B) expressing multiple CpG motifs em-
bedded in a phosphorothioate backbone activate B cells and stimulate
plasmacytoid dendritic cells (pDCs) to secrete tumor necrosis factor–a
(TNFa) (6, 7). In contrast, D-class ODN (D-ODN; CpG-A) contain a phos-
phodiester central palindromic CpG motif capped at each end by a
phosphorothioate poly(G) tail (7, 8). The combination of the central
palindrome and flanking poly(G) enables D-ODN to adopt complex
nanometer-sized multimeric structures stabilized by Hoogsteen base pairs
and confers them their property to stimulate high levels of interferon-a
(IFNa) from pDCs (8–10). The D-ODN–induced robust IFNa response
may have potential benefits in the prevention/treatment of viral in-
fections or malignancies. Unfortunately, the formation of such higher-
order multimeric structures complicates the manufacturing process of
D-ODN, precluding them from human clinical trials (11). Two addi-1Department of Biological Sciences, Middle East Technical University, 06800 Ankara,
Turkey. 2Department of Molecular Biology and Genetics, Bilkent University, 06800
Ankara, Turkey.
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†Corresponding author. E-mail: mgursel@metu.edu.tr
www.Sctional IFNa-inducing CpG ODN classes have also been developed
(designated as C and P classes) (12–14). However, type I IFN–inducing
potency of C-class ODN is substantially low, and the P-class ODN de-
pends on “high-salt buffers” to form IFNa-stimulating concatemeric
structures, making them unpredictable for clinical applications.
A simple strategy to convert a conventional K-ODN into a type
I IFN inducer is to multimerize the ODN using polycationic peptides
(15–17). However, polycation-induced condensation of short thera-
peutic ODN generates aggregates but not ordered nanostructures. To
date, efforts to improve ODN condensation largely focused on de-
velopment of new condensing agents such as poly(amido amine) den-
drimers (18), whereas the impact of ODN secondary structure on
condensation efficiency remained largely ignored. On the basis of
recent reports showing the possibility of spontaneous end-to-end ag-
gregation of short palindromic DNA fragments into rod-like structures
(19), we hypothesized that cationic peptide–mediated condensation
of a flexible 20-mer CpG ODN and a partially self-complementary
rigid 12-mer CpG ODN (fig. S1) would generate disparate nanostruc-
tures that can influence the immunostimulatory activity of the final
product.
Here, we report that in contrast to the typical ODN/cationic pep-
tide aggregates formed with the human antimicrobial peptide LL-37,
HIV-derived cationic peptide Tat(47–57) formed stable, nuclease-resistant
nanorings when mixed with a short K-ODN (12-mer). The nanorings
activated pDCs to secrete IFNa and proved to be potent vaccine ad-
juvants in mice. These results demonstrate that K/Tat nanorings can
replicate D-ODN activity and could find application in the clinic as
vaccine adjuvants and anticancer and antiviral agents.ienceTranslationalMedicine.org 7 May 2014 Vol 6 Issue 235 235ra61 1
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 RESULTS
Cationic peptide Tat(47–57)–induced
condensation of a 12-mer K-ODN generates
ordered nanostructures
To assess whether complexation of K-ODN with
cationic peptides of various length, amphiphili-
city, and charge densities would generate well-
defined, stable nanoparticles suitable for clinical
applications, a fixed amount of a 12-mer K-ODN
was mixed with increasing molar ratios of three dif-
ferent cationic peptides: HIV-Tat–derived peptide
(YGRKKRRQRRR; net charge of +8) (20), human
cathelicidin family antimicrobial peptide LL-37
(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES;
net charge of +6) (21, 22), and the shortest biological-
ly active derivative of LL-37, KR-12 (KRIVQRIKDFLR;
net charge of +4) (22). These three cationic peptides
were chosen as representatives of a long amphiphilic
peptide previously shown to have a role in sensing
of extracellular nucleic acids (LL-37; 37-mer; 54%
hydrophilic) (15–17), a short amphiphilic peptide de-
rived from LL-37 (KR-12; 12-mer; 58% hydrophilic),
and a short hydrophilic peptide with well-characterized
cell penetration properties [Tat(47–57); 11-mer; 82%
hydrophilic]. Complexes were then characterized
in terms of their particle size, z potential, and poly-
dispersity index (PI) (Fig. 1A). z Potential is a phys-
ical property exhibited by particles in suspension
and is an important indicator of stability of the par-
ticles in colloidal systems. It shows the amount of
repulsion between similarly chargedmolecules. There-
fore, if the z potential is very low, attractive forces sur-
pass repulsive forces and particles will come together
to form aggregates. Particles with large negative or
positive z potentials that are small in size resist at-
traction and are hence electrically stabilized. In gen-
eral, particles with z potentials larger than +30 mV
or smaller than −30 mV are considered as stable.
Stability is also designated by the PI. In cases where
PI value is greater than 0.5, sample is too polydisperse,
indicating the presence of very large or aggregated
particles. On the basis of the above information, dy-
namic light scattering revealed that the hydrodynamic
sizes of Tat-incorporating complexes were significant-
ly smaller (~300 nm; P = 0.0028 as determined by the
Kruskal-Wallis test for the three highest ODN/peptide
ratios; n = 6) than those incorporating either LL-37
or KR-12 and were independent of ODN/peptide
ratio. z Potential measurements indicated that among
the complexes tested, only three [K/LL-37 (1:8), K/Tat
(1:8), and K/Tat (1:16)] demonstrated sufficiently
high values (>+30 mV) that could be considered as
stable nanoparticles. On the basis of a PI of <0.15, K/Tat
(1:16) was the sole complexation condition that formed
uniform and monodispersed particles. Note that in
contrast to Tat or KR-12, LL-37 has a high molecular
weight, precluding its testing at an ODN/peptide ratioFig. 1. Physical properties of CpG ODN/cationic peptide complexes prepared using var-
ious ODN/peptide ratios. (A) Average particle size (size of each bubble correlates with the
hydrodynamic diameter) and z potential (vertical axis) of each complex. Numbers next to each
bubble represent the mean hydrodynamic size (nm; top), z potential (mV; middle), and PI
(bottom) of two to four separately prepared samples, each measured in triplicate ± SD. Particles
incorporating KR-12, LL-37, and Tat are shown as blue, purple, and red bubbles, respectively.
Increasing ODN/peptide ratio is indicated as an increase in color depth. Particles with a z
potential of >+30 mV are considered to have sufficient stability, and this “stable complex zone”
is indicated by a gray rectangle. (B and C) AFM images showing nanorings formed using K/Tat
(1:16). (D) AFM image of a single nanoring showing the diameter of one condensed building
block (dashed blue circle; about 40 nm) and the 250-nm-long (white bar), 100-nm-wide (black
bar) central hollow area. (E) Three-dimensional topography image of the nanoring demon-
strates its flat nature (thickness of about 8 nm). The AFM results are representative of at least
two independent samples.www.ScienceTranslationalMedicine.org 7 May 2014 Vol 6 Issue 235 235ra61 2
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5of 1:16, because this required preparation of a concentrated LL-37 solu-
tion beyond its solubility limit (~2 to 5 mg/ml). Of interest, all LL-37–
incorporating complexes generated size intensity histograms composed of
two peaks as opposed to a single, well-defined size peak with less heter-
ogeneity when Tat was used (fig. S2A). On the basis of size and z
potential measurements, KR-12 peptide–incorporating complexes were
considered as highly unstable and were not pursued in later studies.
Replacing the 12-mer K-ODN with a 20-mer one resulted in com-
plexes with significantly lower z potentials (P = 0.036 for the highest
ODN/peptide ratios as determined by Student’s t test; table S1), suggest-
ing that the more flexible longer ODN fails to form stable monodisperse
nanoparticles with Tat.
Atomic force microscopy (AFM) analysis of LL-37–incorporating
particles showed aggregates of various sizes and ill-defined shapes (fig.
S2B). Such heterogeneity in particle size and shape would make these ag-
gregates unsuitable for clinical applications. In contrast, the 12-mer K/Tat
peptide combination (1:16) generated 200- to 300-nm–sized nanorings
(Fig. 1, B and C), each made up of smaller condensed building blocks
with diameters of about 40 nm (Fig. 1D). The central hollow area of onewww.Scsuch ring was ~250 × 100 nm (L × W). The nanorings were flat and
had a thickness of ~8 nm (Fig. 1E). K/Tat peptide (1:8) formed a com-
bination of nanorings and individual spherical condensates (fig. S2C),
whereas when a 1:4 ratio was used, only separate spherical condensates
were present (fig. S2D). Such multivalent cation-induced plasmid DNA
condensation into nanorings (or toroids) was previously reported (23, 24).
However, short ODN are quite rigid and are not as easily condensed into
ordered structures (25). It is conceivable that the 11-mer Tat peptide first
condenses the 12-mer ODN to form rigid individual building blocks that
interact with each other to neutralize the local polar charges and sub-
sequently form rings to reduce the surface charge density, a process rem-
iniscent of nanorings formed from nanobelts (26). The 20-mer flexible
ODN with a long overhang would fail to pack as the rigid 12-mer ODN
and would condense into spherical aggregates but not nanorings.
K/Tat nanorings are potent inducers of IFNa secretion from
human pDCs and are nuclease-resistant
To ascertain whether the K/Tat nanorings could reproduce the immuno-
stimulatory activity of D-ODN, human peripheral blood mononuclear 
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 Fig. 2. IFNa-stimulating activity of various CpG
ODN/cationic peptide complexes in hPBMCs in
comparison to D-ODN activity. (A) Complexation
of K-ODN but not its CpG flipped control (K-flip)
with LL-37 and Tat induces IFNa production from
hPBMCs (shown as fold induction over K-ODN–
induced IFNa levels). Only the K/Tat (1:16, 1 mM)
nanorings induced high levels of IFNa that was
not statistically different from D-ODN–stimulated
samples (3 mM optimum dose). Results are the
average ± SD of five to eight different PBMC samples.
For groupwise comparisons, stimulation indexes
(fold induction) were subjected to the Mann-Whitney
U test (n = 5). N.S., not significant. (B) IFNa-inducing
activity correlates with particle stability (the plot
was generated using 1 mM dose for all complexes;
r is the correlation coefficient). (C) D-ODN (3 mMienceTranslationalMedicioptimum D-ODN dose), K/LL-37 aggregates (1:8, 1 mM), and K/Tat nanorings (1:16, 1 mM) triggered IFNa production from pDCs, whereas K-ODN (1 mM) and
unstimulated controls did not. pDCs were defined using a live cell gate (P2) and blood dendritic cell antigen-2 (BDCA-2; also known as CD303)/CD123
double positivity (P1). The ungated BDCA-2−/CD123+ cells are basophils. Results are representative of four independent samples.ne.org 7 May 2014 Vol 6 Issue 235 235ra61 3
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ious molar ratios and concentrations, and the potency of cytokine pro-
duction was compared to that induced by the optimum dose of free
D-ODN (3 mM) (9, 27). Among the 10 different complexes (each tested
using three different doses), only the nanoring forming formulation
triggered IFNa release to levels that were not statistically different from
the D-ODN–induced IFNa [K/Tat (1:16), 1 mM; Fig. 2A and table S2].
LL-37–incorporating aggregates triggered a substantially lower response.
IFNa production was strictly dependent on the presence of the CpG
dinucleotide motif because complexes prepared with a 12-mer GpC
flipped control ODN (K-flip) had no activity (Fig. 2A). IFNa-inducing
activity correlated strongly with the z potential of complexes (Fig. 2B,
r = 0.76), whereas no such correlation was found with respect to par-
ticle size (fig. S3, r = −0.198). Similar to D-ODN–stimulated PBMCs,
ODN/peptide complexes stimulated IFNa production specifically from
pDCs (Fig. 2C).
The effect of ODN backbone chemistry and ODN length was also
determined in experiments where the complexes were prepared with the
maximumODN/peptide ratio (1:8 for LL-37 and 1:16 for Tat) using either
a phosphodiester (PO) 12-mer K-ODNor a 20-mer phosphorothioate (PS)
ODN. Results show that ODN backbone and length had a critical impact
on IFNa-inducing activity of the complexes (fig. S4). For optimal induc-
tion, the use of the 12-mer PS backbone K-ODN was essential. These re-
sults suggest that K/Tat nanorings can be effective D-ODN mimetics.
Of interest, aggregates and nanorings were not cytotoxic (fig. S5A) and
did not trigger inflammasome activation in lipopolysaccharide-primed
thioglycolate-elicited mouse peritoneal macrophages (fig. S5B).www.ScDirect D-ODN activation of pDCs was previously shown to trigger
secretion of IFNa and other soluble factors that synergize to induce
monocytes to secrete high levels of the T helper 1 (TH1)–promoting
chemokine IFNg-inducible protein-10 (IP-10) (28).When secretion of this
chemokine was tested, all Tat-incorporating complexes and only the
K/LL-37 (1:8) complex was found to induce substantial IP-10 production
that was not statistically different when compared to D-ODN–stimulated
samples (Fig. 3A and table S3). As expected, the presence of the CpGmo-
tif was required for this activity, and aggregates or nanorings incorporating
the control ODN K-flip were not active. Similar to D-ODN, K/Tat (1:16)
nanorings increased the percentage of IP-10–producing monocytes about
sevenfold over K-ODN–stimulated samples (Fig. 3B). In contrast to
D-ODN (9, 27), an interesting feature of the nanorings and the aggregates
was their ability to stimulate TNFa release from pDCs (fig. S6) to similar
levels observed with K-ODN–induced samples. Thus, the K-ODN present
in these complexes retained its TNFa-inducing ability, which may further
contribute to the activation of natural killer cells and cytotoxic T cells.
One important factor that affects the in vivo therapeutic activity
of CpG ODN is their susceptibility to degradation by nucleases. Al-
though PS-modified ODN display increased nuclease resistance, they
are still prone to degradation. To assess whether the ODN in nanorings
would be protected from this assault, we compared IP-10–inducing ac-
tivity of untreated versus deoxyribonuclease (DNase)–treated complexes
(Fig. 3C and table S4). Nanorings retained 70 to 80% of their IP-10 stim-
ulatory activity after a 30-min exposure to DNase. In contrast, LL-37/ODN
(1:8) aggregates retained only 40% of their activity, suggesting a lower
efficiency of condensation/protection.ienceTranslationalMedicine.org
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 Tat peptide–induced condensation
enhances cellular internalization
and early endosomal localization
of the K-ODN
Next, using the human pDC-like CAL-1
cells (29), we studied the cellular internaliza-
tion properties and subcellular distribution
of the LL-37/ODN aggregates (1:8) and
K/Tat (1:16) nanorings, because these con-
ditions proved to be the most stable and
potent formulations for their respective
peptides. For this, complexes were prepared
with fluorescein amidite (FAM)–labeled
K-ODN, and cell-associated fluorescence
was measured before and after trypan blue
quenching to enable discrimination be-
tween surface-bound + internalized and
internalized signal only. All samples dis-
played a dose-dependent increase in the
percentage of cells positive for surface-
bound + internalized and internalized ODN
signal before and after trypan blue quench-
ing, respectively (Fig. 4A). About 35% of
cells were positive for internalized K-ODN
at the highest dose. Complexation led to a
significant increase in this number (P <
0.05, 80% for K/LL-37 aggregates and 95%
for K/Tat nanorings). Analysis of mean flu-
orescence intensities (MFIs), reflecting the
quantity of cell-associated ODN, revealedFig. 3. K/LL-37 aggregates and
K/Tat nanorings induce IP-10 se-
cretion from monocytes and in-
crease the nuclease resistance of the associated CpG ODN.
(A) All K-ODN/Tat complexes and only the K/LL-37 (1:8) com-
plex induced IP-10 production comparable to D-ODN–stimulated
activity [determined by enzyme-linked immunosorbent as-
say (ELISA) from 24-hour culture supernatants]. Results arethe average ± SD of five different PBMC samples. For groupwise comparisons, stimulation indexes
(fold induction) were subjected to the Mann-Whitney U test (n = 5). (B) D-ODN (3 mM optimum D-ODN
dose), K-ODN (1 mM), and K/Tat nanorings (1:16, 1 mM) triggered IP-10 production from CD14+ monocytes.
Results are representative of three independent samples. (C) K/Tat nanorings (1:8 and 1:16) protect their
CpG content from nuclease digestion significantly better than K/LL-37 aggregates. Sample means were
compared to the mean of K/LL-37 stimulated group using the Student’s t test (n = 3). *P < 0.05 [P = 0.046
for K/Tat (1:8) and P = 0.013 for K/Tat (1:16)].7 May 2014 Vol 6 Issue 235 235ra61 4
R E S EARCH ART I C L E
 
o
n
 J
un
e 
8,
 2
01
5
st
m
.s
ci
en
ce
m
ag
.o
rg
D
ow
nl
oa
de
d 
fro
m
 that surface-bound + internalized signal increased 26-fold with K/LL-37 and
10-fold with K/Tat (Fig. 4B) over K-ODN alone. However, internalized-
only signal increased only 14-fold with the K/LL-37 aggregates as op-www.ScienceTranslationalMedicine.org 7 Mposed to a 30-fold enhancement when
K/Tat nanorings were used (Fig. 4C).
This suggests that ~50% of LL-37–
incorporating aggregates remain plas-
ma membrane–associated, whereas
almost all of the K/Tat nanorings were
efficiently internalized.
Previous studies have shown that
the differential immune activation
induced by K-ODN versus D-ODN
correlates with their subcellular dis-
tribution profiles in pDCs: K-ODN
localize to late endosomes and trig-
ger TNFa production through the
TLR9-MyD88-IRF5 pathway, whereas
D-ODN accumulate in transferrin-
positive early endosomes and stimulate
IFNa production via a TLR9-MyD88-
IRF7–dependent pathway (27, 30, 31).
Similar to D-ODN and in contrast to
K-ODN, K/LL-37 aggregates and
K/Tat nanorings preferentially local-
ized to transferrin-positive early endo-
somes (Fig. 4D), consistent with their
IFNa-inducing activities.
K/Tat nanoring adjuvanted
vaccines induce potent
TH1-dependent antigen-specific
immune responses in mice
Type I IFNs play important roles in
regulating adaptive immune responses
through both direct and indirect ef-
fects and are considered as the “third
signal” that shapes the effector and
memory T cell pool (32, 33). They con-
tribute to T cell–mediated interleukin-2
secretion from CD4+ central mem-
ory cells (34). Moreover, they directly
trigger clonal expansion and memory
formation in CD8+ T cells (35). These
properties make type I IFN inducers
attractive vaccine adjuvants predomi-
nantly in cases where the development
of immunological memory is taxing.
We therefore chose to compare the vac-
cine adjuvant properties of the ODN/
peptide aggregates and nanorings to
K-ODN using a commercially avail-
able inactivated viral vaccine developed
against one of the most economically
devastating livestock diseases, the foot
and mouth disease (FMD). This vac-
cine is explicitly problematic because
protective antibodies produced by asingle vaccination tend to be short-lived, and subsequent vaccinations
do not stimulate the development of immunological memory (36). As
a consequence, to provide protection, animals have to be vaccinatedFig. 4. Cellular internalization properties and subcellular localization of K/LL-37 aggregates and K/Tat
nanorings. (A) Percent of CAL-1 plasmacytoid-like DCs positive for cell surface–bound and internalized FAM-
labeled ODN (No trypan blue) or internalized ODN alone (+ Trypan blue) after 1-hour incubation with three
different doses (0.16, 0.5, and 1.5 mM) of K-ODN, K/LL-37 aggregates, or K/Tat nanorings. Dot plots show FAM-
associated ODN fluorescence (FL1) versus forward scatter (FSC). (B) Quantification of total cell-associated fluo-
rescence (based on MFIs), revealing that MFI increased 26-fold with K/LL-37 and 10-fold with K/Tat over K-ODN
alone at the highest ODN dose. (C) Quantification of internalized fluorescence (based on MFIs obtained after
trypan blue quenching) showing that compared to K-ODN alone, K/LL-37 aggregates and K/Tat nanorings im-
proved internalized ODN amount 14- and 30-fold, respectively. (D) Confocal microscopy of CAL-1 cells treated
with free or peptide-associated ODN (green) for 1 hour shows that K/LL-37 aggregates and K/Tat nanorings, but
not K-ODN, localize to transferrin-positive (red) vesicles.ay 2014 Vol 6 Issue 235 235ra61 5
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with limited resources, where “vaccine dose sparing” could critically con-
tribute to economic welfare, especially during an epidemic (37). Thus, to
test whether we could expand the supplies of the FMD vaccine and im-
prove long-term immunity, mice were primed and boosted (days 0 and
28) with a 5× lower dose of the FMD vaccine (0.5 mg; determined in pre-
liminary experiments) in the absence or presence of the adjuvants (2 mg
each of K-ODN, K/LL-37 aggregates, or K/Tat nanorings). This dose of
CpG ODN is lower than the typical dose used in mouse vaccine studies
(10 to 50 mg) (38) and was chosen to enable comparison of vaccine ad-
juvant potencies. Long-term FMD-specific antibody responses were eval-
uated from sera of immunized mice collected 180 days after priming. The
data are expressed as mean log2 reciprocal immunoglobulin G (IgG) titers ±
SD. One-way analysis of variance (ANOVA) and the Tukey’s honestly sig-
nificant difference (HSD) post hoc test were used to determine which groups
were significantly different from the rest. The results showed that mice
vaccinated with the FMD vaccine generated similar titers of FMD-specific
IgG1 antibody compared to those immunized with the vaccine plus ad-
juvants (Fig. 5A and table S5). In contrast to the adjuvanted groups, FMD
vaccine alone did not trigger detectable FMD-specific IgG2a antibody re-
sponse (Fig. 5B). Notably, K/Tat nanorings elicited 6- and 33-fold higher
titers of FMD-specific IgG2a when compared to K + FMD and K/LL-www.Sc37 + FMD vaccinated groups, respectively (Fig. 5B, P < 0.05 based on
the HSD values shown in table S5). K/Tat nanorings were the only ad-
juvant group that induced a substantial and significant increase in anti-
FMD IgG2a/IgG1 ratio, consistent with a shift toward a predominantly
TH1-dominated response (Fig. 5C and table S5). Finally, as a measure of
cell-mediated immunity, in vitro FMD antigen restimulation of spleno-
cytes harvested from immunized mice revealed that only the group
adjuvanted with the K/Tat nanorings induced a significant increase in
antigen-specific IFNg production (3.8-fold) when compared to the FMD
vaccinated group (Fig. 5D and table S5). These results suggest that K/Tat
nanorings are more effective in stimulating antigen-specific T cell responses.
Several studies have previously shown that in the EG.7/EL4 murine
lymphoma model, CpG ODN treatment resulted in significant suppres-
sion of tumor growth (39–43). Therefore, we next compared the anti-
tumor vaccine adjuvant activities of K-ODN versus the K/Tat nanorings
by therapeutically vaccinating C57BL/6 mice bearing ovalbumin (OVA)–
expressing EG.7 thymoma tumors with the model tumor antigen OVA
plus the adjuvants. C57BL/6 mice with palpable tumor mass were injected
intraperitoneally with 25 mg of OVA plus K-ODN or K/Tat nanorings
(10 mg of ODN, each) 1 week apart. As seen in Fig. 6A, OVA + K/Tat
nanorings significantly decreased the growth of subcutaneous tumors over
time when compared to OVA + K-ODN–treated groups (Fig. 6A; P =ienceTranslationalMedicine.org
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 0.0005, 0.0004, 0.0003, 0.0024, and 0.0001
on days 2, 4, 6, 8, and 10, respectively). Av-
erage tumor weight of the K/Tat nanoring
adjuvanted group was about fourfold lower
at sacrifice (P = 0.0001, Fig. 6B), and the
tumorsweremuch smaller than those formed
in the K-ODN–incorporating group (Fig.
6C). In contrast to the K-ODN adjuvanted
group, K/Tat nanorings stimulated signif-
icant expansion in the number of CD8+ T
cells (from 5.5 ± 0.4 to 10.1 ± 0.2, P =
0.0001, Fig. 6D) and induced 2.4-fold more
antigen-specific IFNg from this popula-
tion (P = 0.0017, Fig. 6E). These results
suggest that K/Tat nanorings are more
effective than the K-ODN in stimulating
tumor-specific cytotoxic T cell responses.
K/Tat nanoring vaccine adjuvant
activity is dependent on the
presence of pDCs
To assess whether K/Tat nanoring activ-
ity requires the presence of pDCs, we
next depleted this cell population in vivo
to examine the role of these cells in the
induction of antibody responses to the
model antigen OVA. For this, mice were
treated intraperitoneally with phosphate-
buffered saline (PBS) (undepleted groups)
or an antibody to mouse plasmacytoid den-
dritic cell antigen 1 (mPDCA-1), and then
immunized 24 hours later with K/Tat +
OVAorD-ODN+OVA.Depletion of pDCs
was confirmed in the peripheral blood on
the day of immunization (Fig. 7A). OVA-
specific IgG1 and IgG2a antibody responsesFig. 5. FMD-specific immune responses generated in mice. (A and B) FMD serotype O–specific IgG1
(A) and IgG2a (B) log reciprocal titers were determined from sera of mice 6 months after priming. Each2
circle corresponds to the antibody titer of individual mice, and horizontal lines indicate mean antibody
titers ± SD. (C) IgG2a/IgG1 titer ratios of individual mice (open circles) and group averages (horizontal
lines). (D) FMD antigen–specific IFNg production was determined from in vitro antigen restimulated spleno-
cytes (black bars) of immunized mice. Gray bars show the response in the absence of antigen. Results are the
average ± SD of five mice. *P < 0.05 for all groups based on Tukey’s HSD post hoc test using one-way ANOVA
(HSD values and comparisons are shown in table S5).7 May 2014 Vol 6 Issue 235 235ra61 6
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 were evaluated from sera of immunized mice collected 14 days after
immunization (Fig. 7, B and C). OVA-specific IgG1 titers were similar
in all OVA-immunized groups regardless of their pDC depletion sta-
tus or adjuvant identity (Fig. 7B). In sharp contrast, K/Tat and D-ODN
adjuvanted groups generated 75- and 85-fold higher OVA-specific IgG2a
titers when compared to antigen alone, and this activity was severely im-
paired in pDC-depleted mice (Fig. 7C, P = 0.0404 for K/Tat and D-ODN–
undepleted versus pDC-depleted groups; Mann-Whitney U test; n = 3).
These results suggest that K/Tat- and D-ODN–induced pDC activa-
tion is essential for the generation of TH1-dominated responses to OVA
vaccination.DISCUSSION
Type I IFNs play important roles in regulating innate and adaptive
immune responses by participating in maturation and trafficking of
DCs, establishment of effector and memory T cell responses, and stim-www.Sculation of humoral immunity. Therefore, development of type I IFN
inducers as antiviral/anticancer agents and/or vaccine adjuvants may
have potential clinical applications. The therapeutic potential of one
such type I IFN inducer, D-ODN, remained largely unexplored owing
to formation of uncontrollable product aggregation that complicates
their manufacture and hampers their approval by the U.S. Food and
Drug Administration. The current study aimed to convert a conven-
tional K-ODN suitable for clinical use but devoid of IFNa-stimulating
activity into a potent type I IFN inducer.
The results showed that a short (12-mer) K-ODN and the HIV-
derived cationic peptide Tat(47–57) condensed to form 200- to 300-nm–
sized uniform nanorings but not aggregates. In contrast to the typical
ODN/cationic peptide aggregates formed with LL-37, the nanorings
were significantly more nuclease-resistant and stimulated secretion of
large amounts of IFNa from pDCs and IP-10 from monocytes. Flow
cytometry and confocal studies confirmed that the nanorings enhanced
ODN internalization and localization to transferrin-positive early endo-
somes, a subcellular distribution pattern consistent with efficient IFNaFig. 6. Antitumor vaccine adjuvant activities of K-ODN versus the K/Tat
nanorings. (A) EG.7 cells (2.5 × 106) were subcutaneously inoculated into
injection, excised tumors were weighed (B) and photographed (C). Spleno-
cytes (2.5 × 106/ml) were stimulated in the absence or presence of SIINFEKLC57BL/6 mice. When the tumor mass became palpable (≥50 mm3, typically
5 days later), the tumor-bearing mice were injected intraperitoneally with
25 mg of OVA + 10 mg of K-ODN (open triangles) or 25 mg of OVA + 10 mg of
K/Tat nanorings (closed circles). Data represent the progression in mean tumor
volumes ± SD of five mice per group. (B and C) Twelve days after tumor cellpeptide (2 mg/ml) for 5 hours together with brefeldin A (10 mg/ml). (D and E)
Cells were stained for cell surface CD8 expression (D), and after gating on this
population, intracellular IFNg production (E) was assessed by flow cytometry.
Statistical comparison between groups was based on two-tailed unpaired Stu-
dent’s t test (n = 3 to 5).ienceTranslationalMedicine.org 7 May 2014 Vol 6 Issue 235 235ra61 7
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 production. In vivo, K/Tat nanorings proved to be potent vaccine ad-
juvants and induced TH1-dominated long-term immune response in
mice vaccinated with a 5× lower dose of a commercially available in-
activated viral vaccine against the FMD vaccine. Therapeutic vaccina-
tion of C57BL/6 mice bearing OVA-expressing EG.7 thymoma tumors
with OVA plus K/Tat nanorings generated superior antitumor immu-
nity when compared to mice treated with OVA plus K-ODN. The in
vivo vaccine adjuvant activity of the nanorings was similar to D-ODN
and was severely impaired in mice depleted of pDCs, suggesting that
pDC activation and their type I IFN production are critical for the vac-
cine adjuvant activity of the nanorings.
Multimerized CpG ODN are believed to be retained in early en-
dosomes where they cross-link TLR9 and trigger MyD88/IRF7-
mediated intracellular signaling pathways, leading to IFNa secretion
from pDCs (27, 30, 44–47). Although K-ODN were shown to trigger
production of this cytokine from pDCs after their conjugation/adsorption
onto nanoparticles (44, 48) or their multimerization through association
with cationic liposomes (45), heat shock protein 90 (49), or long cation-
ic peptides (15–17), such delivery methods suffer from cumbersome nano-
particle production protocols, potential toxicity/immunity associated
with the carrier, or unpredictable aggregation/precipitation of the product,
deeming them unsuitable for clinical applications. The ease with whichwww.ScienceTranslationalMedicine.orgthe nanorings form and their effectiveness
for vaccine dose–sparing applications and
stimulating antitumor immunity suggest
that as D-ODN surrogates, theymay prove
to be of value as antiviral or anticancer
agents and vaccine adjuvants in the clinic.
Although these results are encourag-
ing for the potential clinical development
of a type I IFN inducer, the current study
had the following major limitation: All in
vivo data were based on murine studies.
The cellular distribution of TLR9 in the
mouse is much broader than in the hu-
man and includes myeloid DCs, pDCs,
monocytes, macrophages, and B cells (as
opposed to restricted expression in pDCs
and B cells in the human) (1–14). There-
fore, nonhuman primate studies where
the cellular expression of TLR9 is similar
to humans would be better suited to pre-
dict in vivo adjuvant activity.MATERIALS AND METHODS
Study design
For all experiments, the minimum sam-
ple size was determined to detect a differ-
ence between group means of two times
the observed SD, with a power of 0.8 and
a significance level of 0.05, using the power
and sample size calculator (http://www.
statisticalsolutions.net/pss_calc.php). On
the basis of this, the calculated minimum
sample sizes ranged from two to three de-
pending on the experiment. Actual sam-ple size for mouse studies was three to five per group. Throughout
the study, hPBMCs were collected from healthy donors (15 different
volunteers; ages 20 to 45 years; sex: 8 males and 7 females). All sam-
ples were randomized but not blinded.
Reagents
Endotoxin-free ODN were purchased from Integrated DNA Technologies
BVBA. Sequences of ODN used were as follows: K3, ATCGACTCTCG-
AGCGTTCTC; K3-flip, ATGCACTCTGCAGGCTTCTC; K23, TCGAG-
CGTTCTC; K23-flip, TGCAGGCTTCTC; D35, GGtgcatcgatgcaggggGG.
Bases shown in capital letters are phosphorothioate, and those in lower
case are phosphodiester. The cationic peptides LL-37 (LLGDFFRKSKE-
KIGKEFKRIVQRIKDFLRNLVPRTES), KR-12 (KRIVQRIKDFLR), and
HIV Tat(47–57) (YGRKKRRQRRR) and the OVA (257–264) SIINFEKL
peptide were synthesized by AnaSpec.
Preparation and characterization of CpG
ODN/peptide complexes
CpGODNK23 (12-mer), K3 (20-mer), or their GpC (flip) controls were
mixed at different molar ratios (1:1, 1:2, 1:4, 1:8, or 1:16) with the anti-
microbial cationic peptides LL-37 (37-mer; +6 charge), KR-12 (11-mer,
+4 charge), or Tat peptide (11-mer; +8 charge) and were incubated forFig. 7. The vaccine adjuvant activities of K/Tat nanorings and D-ODN are dependent on the pres-
ence of pDCs. Mice were treated intraperitoneally with PBS (undepleted groups) or an antibody to
mPDCA-1 (500 mg per mouse) and then immunized 24 hours later with K/Tat + OVA or D-ODN + OVA
(15 mg of ODN and 10 mg of OVA per mouse). (A) Depletion of pDCs was confirmed in the peripheral blood
on the day of immunization. Dot plots show representative percentages of the Ly6C/B220 double-positive
pDCs in pDC-undepleted (upper panels) and pDC-depleted (lower panels) groups. (B and C) OVA-specific
IgG1 (B) and IgG2a (C) log2 reciprocal titers were determined from sera of mice 14 days after priming. Each
circle corresponds to the antibody titer of individual mice, and horizontal lines indicate mean antibody
titers ± SD. *P = 0.0404 based on Mann-Whitney U test (n = 3).7 May 2014 Vol 6 Issue 235 235ra61 8
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 30 min at room temperature. Complexes were characterized by dynamic
light scattering, z potential measurement, and AFM. For size and z
potential measurements, a Malvern Zetasizer Nano ZS was used. The hy-
drodynamic diameters are reported as the intensity average measured from
two independent samples [50× diluted with DNase/RNase (ribonuclease)–
free distilled water]. Size and morphology of complexes were determined
by AFM as follows: 5 ml of each sample (in DNase/RNase-free water)
was deposited onto a Mica sheet and was allowed to dry at room temper-
ature for 30 min. Noncontact mode images were taken using a PSIA
XE-100E model AFM. Tap190AI-G model tips were from NanoSensors.
Tips’ resonance frequency and force constant were 130 kHz and 20 N/m,
respectively. Scan rate was kept at 0.73 to 0.79 Hz. Images were analyzed
with XEI 1.6 software.
Determination of immunostimulatory activity of complexes
PBMCs from healthy donors or mouse splenocytes (2 × 106 to 4 ×
106/ml) were cultured in RPMI 1640 medium containing 5% fetal calf
serum, penicillin (50 U/ml), streptomycin (50 mg/ml), L-glutamine
(0.3 mg/ml), 1 mM nonessential amino acids, 1 mM sodium pyruvate,
10 mM Hepes, and 105 M 2-mercaptoethanol. Depending on the
identity of the cytokine or chemokine intended for measurement, cells
were stimulated with 0.3 to 3 mM free ODN or its complexes for a
period of 5 to 24 hours. In some experiments, free CpG ODN and
CpG ODN/peptide complexes were treated with 1.1 IU of DNase I
(from bovine pancreas, Roche) per microgram of ODN for 30 min
before stimulation. IFNa-secreting cells were analyzed with Miltenyi
Biotec’s IFN-a Secretion Assay Detection Kit from PBMCs in accord-
ance with kit instructions. For intracellular cytokine staining, cells
were stimulated in the presence of brefeldin A (10 mg/ml) as previous-
ly described (9, 27). For flow cytometric analysis of cells, the following
antibody clones were used: BDCA-2–PE (phycoerythrin) (AC144) from
Miltenyi Biotec; CD123-PE-Cy5 (9F5), CD14-FITC (fluorescein isothio-
cyanate) (M5E2), IP-10–PE (6D4/D6/G2), and TNFa-PE (MAb11)
from BD Biosciences; and CD8-PE-Cy5 (53-6.7) and IFNg-PE (XMG1.2)
from BioLegend. All staining protocols were performed as previously
described (9, 27). Stained cells were analyzed (20,000 to 100,000 events)
on a BD Accuri C6 flow cytometer (BD Biosciences) following proper
electronic compensation.
Cytokine ELISA
Ninety-six–well microtiter plates (Millipore) were coated with antibodies
specific to human IFNa or IP-10 or mouse IFNg. The plates were blocked
with PBS–5% bovine serum albumin (BSA). Supernatants from cultured
cells were added, and their cytokine content was quantitated by the
addition of biotin-labeled anti-cytokine antibody followed by phosphatase-
conjugated avidin and phosphatase-specific colorimetric substrate as
previously described (9, 27). Standard curves were generated using known
amounts of recombinant human cytokine. All assays were performed
in triplicate, and all washing steps were performed with PBS–0.05%
Tween 20.
Analysis of cell surface binding and internalization of ODN
CAL-1 human plasmacytoid-like DCs (1 × 106/ml) were incubated
with FAM-labeled ODN or its complexes (0.16 to 1.5 mM) for
1 hour at 37°C and extensively washed with PBS before analysis on
a flow cytometer. To detect internalized ODN, surface-bound ODN-
FAM signal was quenched using 0.2% trypan blue (mixed 1:1 with
the sample).www.ScConfocal microscopy
CAL-1 cells (1 × 106/ml) were incubated with Cy5-labeled ODN or its
complexes together with transferrin–Texas Red conjugate (20 mg/ml)
(marker for early endosomes) at 37°C for 1 hour. All samples were
washed, and live cells were immediately analyzed with a confocal mi-
croscope under a 63× objective (Carl Zeiss, LSM).
Immunization studies
All animal studies were conducted with previous approval of the animal
ethics committee of Bilkent University.
The FMD vaccine was prepared and provided by the FMD Insti-
tute (Ankara, Turkey). This monovalent vaccine formulation contained
FMD vaccine O/TUR/07 inactivated antigen in double oil emulsion
with Montanide ISA 206 (SEPPIC). Six- to 8-week-old female BALB/c
mice (five per group) were immunized two times (intraperitoneally, days
0 and 15) using 5× lower dose of the optimal licensed monovalent vac-
cine (0.5 mg per mouse) alone or mixed with K-ODN, K/LL-37 (1:8), or
K/Tat (1:16). CpG ODN dose per mice was adjusted so that each animal
received a 5× lower dose (2 mg) of ODN than the optimal adjuvant dose
used in mice (10 to 50 mg).
To follow long-term antigen-specific antibody responses, sera were
collected 180 days after priming, and FMD-specific antibody titers
were determined by ELISA. Briefly, Immulon 1B plates were coated
overnight with 50 ml of rabbit anti–Ser-O antibody (1:2000 dilution)
at 4°C and blocked with PBS–5% BSA. Diluted supernatant (1:20) of
the cell lysate of FMD vaccine–infected baby hamster kidney cells was
then added to the plates in PBS (50 ml per well) and incubated
overnight at 4°C. Diluted mouse serum (80×) was serially diluted
twofold, and specific antibodies were detected using goat anti-mouse
IgG1 or IgG2a alkaline phosphatase conjugate (1:3000 dilution) fol-
lowed by PNPP (p-nitrophenyl phosphate, disodium salt) substrate ad-
dition. Color development was followed at optical density (OD) 405 nm
with a microplate reader. Antibody titers were expressed as the recip-
rocal log2 of the last dilution that gave an OD of plus 3 SDs above the
average OD of all dilutions from nonimmunized control mice.
FMD antigen–specific T cell responses generated in
immunized mice were assessed using the IFNg production
from in vitro FMD antigen (3 mg/ml) restimulated
spleen cells by ELISA
EG.7 tumor cells (2.5 × 106 per mice) were injected subcutaneously
into the dorsal flank of C57BL/6 mice (five per group). After the tu-
mors reached a palpable size (≥50 mm3), groups of mice received two
intraperitoneal injections of 25 mg of OVA plus K-ODN or K/Tat (10 mg
of ODN, each) 1 week apart. Five days after the first intraperitoneal
injection, tumor volumes were measured with a caliper every other day
and recorded as length × width × height. Animals were sacrificed 8 days
after the second intraperitoneal injection, and tumors were excised
and weighed. Splenocytes (2.5 × 106/ml) were stimulated in the absence
or presence of SIINFEKL (2 mg/ml) OVA 257–264 class I (Kb)–restricted
peptide epitope for 5 hours together with brefeldin A (10 mg/ml). Cells
were stained for cell surface CD8 expression, fixed and permeabilized,
and then stained for intracellular IFNg production. Results were ana-
lyzed by flow cytometry on CD8-gated cells.
For pDC depletion experiments, BALB/c mice (three per group)
were injected intraperitoneally with PBS (pDC-undepleted groups) or
with antibody to mPDCA-1 (500 mg) (Miltenyi Biotec; clone JF05-
1C2.4.1; pure-functional grade) 24 hours before immunization withienceTranslationalMedicine.org 7 May 2014 Vol 6 Issue 235 235ra61 9
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confirm pDC depletion 24 hours after antibody injection, 100 ml of
blood was collected from tail veins into heparinized tubes and red blood
cells were lysed using ACK lysis buffer. After Fc blocking with an antibody
to CD16/32, peripheral blood cells were stained with FITC-conjugated
antibody to Ly6C and Alexa Fluor 647–conjugated antibody to CD45R/
B220 for 30 min at room temperature and washed with PBS containing
1% BSA. The percentage of the Ly6C/B220 double-positive pDCs was
determined with flow cytometry. Sera were collected 14 days after
priming, and OVA-specific antibody titers were determined by ELISA.
Briefly, Immulon 1B plates were coated overnight with 50 ml of OVA
protein (7.5 mg/ml) at 4°C and blocked with PBS–5% BSA. Diluted mouse
serum (8×) was serially diluted fourfold, and specific antibodies were
detected using goat anti-mouse IgG1 or IgG2a alkaline phosphatase
conjugate (1:3000 dilution) followed by PNPP substrate addition.
Color development was followed at OD 405 nm with a microplate reader.
Antibody titers were expressed as the reciprocal log2 of the last dilution
that gave an OD of plus 3 SDs above the average OD of all dilutions from
nonimmunized control mice.
Statistical analysis
For groupwise comparisons, stimulation indexes (fold induction) were
subjected to the Mann-Whitney U test. Comparison of log2-transformed
FMD-specific antibody titers and FMD-specific IFNg production between
groups was performed using one-way ANOVA with Tukey’s HSD post
hoc test (P < 0.05). For comparison of antitumor responses elicited in
mice immunized with OVA + K-ODN versus OVA + K/Tat nanorings,
two-tailed unpaired Student’s t test was used. For all comparisons, 95%
confidence intervals were used and P values of <0.05 were considered
significant. All analyses were done with the SPSS 22.0 statistics software.
Statistical tests used to determine significance, sample sizes, and P values
are provided in individual figure legends or in supplementary tables.D
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 SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/6/235/235ra61/DC1
Method
Fig. S1. Secondary structure predictions of the 20-mer CpG ODN (left) and the 12-mer CpG
ODN (right) were generated using the M-fold program.
Fig. S2. Physical properties of K-ODN/cationic peptide complexes prepared using various
ODN/peptide ratios.
Fig. S3. IFNa-inducing activity does not correlate with particle size.
Fig. S4. IFNa-stimulating activity of various K-ODN/cationic peptide complexes in hPBMCs.
Fig. S5. K-ODN/cationic peptide complexes are not cytotoxic and do not trigger inflammasome
activation.
Fig. S6. K-ODN/cationic peptide complexes trigger TNFa production from pDCs.
Table S1. Average particle size, PI, and z potential measurements of complexes prepared with
the 12- and 20-mer K-ODN.
Table S2. Raw data and statistical significance testing for Fig. 2A.
Table S3. Raw data and statistical significance testing for Fig. 3A.
Table S4. Raw data and statistical significance testing for Fig. 3C.
Table S5. Results of Tukey’s HSD post hoc test using one-way ANOVA for Fig. 5.REFERENCES AND NOTES
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Editor's Summary
 
 
 
antiviral or anticancer agents.
antitumor immunity in a mouse cancer model. These data suggest that these nanorings may be valuable as either 
1 immune responses in mice vaccinated with inactivated foot and mouth disease virus, and improvedHinduced T
response in human plasmacytoid dendritic cells. The ODN nanorings were then tested in animal models. They 
The authors found that these nanorings targeted the ODN to early endosomes and induced a type I interferon
forming a nanoring.
 to multimerize K-type ODN,57)−(47 use the HIV-derived peptide Tatet al.desired immune response. Now, Gungor 
limitations to widespread use of ODN as an adjuvant, one of which is structurally optimizing the ODN to induce the
both preventing and treating infectious disease and cancers in animal models and early clinical trials. Yet, there are 
Hence, ODN are considered prime candidates for use as adjuvants. Indeed, they've been shown to be effective for
oligodeoxynucleotides (ODN) are short single-stranded synthetic DNA molecules that activate the immune system. 
they modify the immune response to the vaccine antigen. CpG−−Adjuvants are vaccines' little helpers
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